Tracheal fistula associated with bevacizumab 20 months after mediastinal radiation.
Department of Internal Medicine, Division of Respiratory Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Japan. otedih@belle.shiga-med.ac.jp
Hideto
H
Yamada
Wataru
W
Shigemori
Yasushi
Y
Ryujin
Hiroshi
H
Wada
Tetsuya
T
Oguma
Makoto
M
Osawa
Taishi
T
Nagao
Yasutaka
Y
Nakano
D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D059248:Chemoradiotherapy / Q000009:adverse effects*; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D005402:Fistula / Q000139:chemically induced* / Q000175:diagnosis*; D005500:Follow-Up Studies; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000175:diagnosis*; D014057:Tomography, X-Ray Computed; D014133:Tracheal Diseases / Q000139:chemically induced* / Q000175:diagnosis*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab